IP Library › Granted Patent US 12,486,493
Granted Patent B2
US 12,486,493 · App. 17/562,443 · Granted Dec 2, 2025

Precursor cells of induced pluripotent stem cell (IPSC)-derived mesenchymal stem cells and method for preparing the same

Inventor: Sue Kim (Seoul, KR)
Assignee: BREXOGEN INC.
C12N5/0662C12P1/00C12N2500/00C12N2500/84C12N2501/115C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,493
App. No.
17/562,443
Granted
Dec 2, 2025
Kind
B2
Abstract

The present disclosure relates to precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and a preparation method therefor. The precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells of the present disclosure have enhanced functionality and excellent proliferative capacity compared with typical mesenchymal stem cells or induced pluripotent stem cell-derived mesenchymal stem cells.

Claims (11)

1 . A method for preparing induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells, the method comprising:

culturing induced pluripotent stem cells in a medium containing fetal bovine serum (FBS) and basic fibroblast growth factor (bFGF) for 1 to 10 days; and

isolating SSEA-4(−) cells and culturing the SSEA-4(−) cells in a medium containing FBS and bFGF for 1 to 10 days.

2 . The method of claim 1 , wherein the medium contains 5 to 20% (v/v) FBS.

3 . The method of claim 1 , wherein the medium contains 1 to 20 ng/ml bFGF.

4 . A method for producing exosomes, the method comprising:

culturing induced pluripotent stem cells in a medium containing FBS and bFGF for 1 to 10 days;

isolating SSEA-4(−) cells and culturing the SSEA-4(−) cells in a medium containing FBS and bFGF for 1 to 10 days;

further culturing the cultured SSEA-4(−) cells in a cell culture medium; and

separating exosomes from the cell culture medium.

5 . The method of claim 4 , wherein the cell culture medium contains exosome-depleted fetal bovine serum.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2021
From: KIM, SUE
To: BREXOGEN INC.
Reel/Frame 058483/0251 →
Priority Claims (2)
KR 10-2019-0091269 · Jul 26, 2019 · national
KR 10-2019-0173078 · Dec 23, 2019 · national
Continuity (3)
Division 16780050 · Feb 3, 2020
Continuation PCTKR2019018426 · Dec 24, 2019
Related Publication 20220119771A1 · Apr 21, 2022
References Cited (39)
US 7569385B2 · Haas · 2009 [cited by applicant]
US 8962321B2 · Kimbrel et al. · 2015 [cited by applicant]
US 10080730B2 · Jeffs et al. · 2018 [cited by applicant]
US 20080081370A1 · Hematti · 2008 [cited by examiner]
US 20110182866A1 · Mcniece · 2011 [cited by applicant]
US 20150118198A1 · Sadiq et al. · 2015 [cited by applicant]
US 20160130556A1 · Hantash · 2016 [cited by applicant]
US 20190017032A1 · Firas et al. · 2019 [cited by applicant]
US 20190117701A1 · Ikeyama et al. · 2019 [cited by applicant]
US 20190269739A1 · Brodie et al. · 2019 [cited by applicant]
US 20200338136A1 · Kim · 2020 [cited by examiner]
US 20210060081A1 · Kim · 2021 [cited by examiner]
KR 1020190083932A · 2019 [cited by applicant]
WO WO2007123363A1 · 2007 [cited by applicant]
WO WO2015050963A1 · 2015 [cited by applicant]
WO WO2017156580A1 · 2017 [cited by applicant]
WO WO2018009147A1 · 2018 [cited by applicant]
WO WO2019135645A1 · 2019 [cited by applicant]
Weist et al., Stem Cells and Development, 2018, vol. 27, No. 3, pp. 166-183. (Year: 2018). [cited by examiner]
Kim et al, Int J Mol Sci, 2018, vol. 19, 16 pages. (Year: 2018). [cited by examiner]
Office Action of China Patent Application No. 201980098785.1, issued on Jul. 15, 2023. [cited by applicant]
EESR of Europe Patent Application No. 19939428.9, issued on Sep. 12, 2022. [cited by applicant]
Office Action from corresponding U.S. Appl. No. 16/780,050, issued on Feb. 1, 2021. [cited by applicant]
Office Action from corresponding U.S. Appl. No. 16/780,050, issued on Apr. 12, 2021. [cited by applicant]
Office Action (Final) from corresponding U.S. Appl. No. 16/780,050, issued on Oct. 25, 2021. [cited by applicant]
Epigenetic rejuvenation of mesenchymal stromal . . . _ Stem Cell Reports Sep. 9, 2014;3(3)414-22. [cited by applicant]
Exosomes Secreted from Induced Pluripotent Stem . . . _Int J Mol Sci.Oct. 11, 2018;19(10)3119. [cited by applicant]
Human placenta and bone marrow derived MSC . . . _Differentiation. Apr. 2007;75(4)279-91. [cited by applicant]
One-step derivation of mesenchymal stem cell . . . _PLoS One 2012;7(3)e33225. [cited by applicant]
Reviewing and updating the major molecular . . ._Stem Cells Dev. May 1, 2013;22(9)1455-76. [cited by applicant]
Minimal criteria for defining multipotent . . ._Cytotherapy.2006;8(4)315-7. [cited by applicant]
Comparative characteristics of mesenchymal stem . . ._Exp Hematol.Nov. 2005;33(11)1402-16. [cited by applicant]
Derivation and immunological characterization of . . ._Exp Hematol.Epub Jan. 7, 2008. [cited by applicant]
Different populations and sources of human . . ._Cell Commun Signal. May 2011 14 9 12. [cited by applicant]
Human Mesenchymal Stromal Cells from Different . . ._Stem Cells Int.Epub Dec. 6, 2015. [cited by applicant]
International Search Report from corresponding PCT/KR2019/018426, dated Apr. 24, 2020. [cited by applicant]
Consentius, et al. (2018) “In Situ Detection of CD73+ CD90+ CD105+ Lineage: Mesenchymal Stromal Cells in Human Placenta and Bone Marrow Specimens by Chipcytometry.” [cited by applicant]
Tsao, et al. (2014) Mesenchymal Stem Cell Derived Exosomes: A New Hope for the Treatment of Cardiovascular Disease?, [cited by applicant]
Notification of Reason for Refusal of KR Patent Application No. 10-2019-0173078 issued on Mar. 18, 2021. [cited by applicant]